CSF3 and lymphoma: In support of our findings, results from a 5-year, long-term, phase 3, follow-up study (not restricted to poor mobilizers) suggested that the use of G-CSF + plerixafor did not have a negative outcome on PFS and OS in patients with lymphoma, with more than a half of patients with lymphoma remaining alive 5 years post transplantation [17].